Women with breast cancer do not receive timely genetic testing or have adequate access to effective genetic counseling, which may compromise treatment decisions, according to research from Stanford and the University of Michigan.
A common signaling pathway unites diverse fibrotic diseases in humans, Stanford researchers have found. An antibody called anti-CD47, which is being tested as an anti-cancer agent, reverses fibrosis in mice.
Pretreatment with a stem-cell-activating protein significantly enhances healing in mice, Stanford researchers say. The approach could eventually help people going into surgery or combat heal better from injuries they sustain.
Inside Stanford Medicineis a twice-monthly newspaper that reports on the accomplishments and activities of the faculty, staff and students in the Stanford Medicine community. To suggest a story or to get more information, contact editor John Sanford at (650) 723-8309 or email@example.com.
You're receiving this newsletter because you registered with us.
Not interested anymore? Unsubscribe here.